It looks like nothing was found at this location. Maybe try one of the links below or a search?
Popular Articles:
-
Response to EPO consultation: Don’t impose oral proceedings by videoconference
-
Quality at the EPO – One Modest and one Serious Proposal
-
‘Opposition against Unitary Patent comes from fearful lawyers and critics who only have a theoretical interest’
-
Leading German patent law firms criticize European Patent Office
-
UPC: four reasons on why the PPA is not legally in force
-
The EPO’s Vision (V) – Trust
Recent Articles:
-
Announcement of the national program “MOVER” raises expectations for an increase in patent filings for green technology
-
UPC “saisie-contrefaçon” Part III: the “C-Kore” case
-
Brazil: Animal Health and Patent Litigation
-
China’s Supreme People Court decides FRAND dispute in ACT v Oppo
-
UPC “saisie-contrefaçon” Part II: the “OERLIKON” case
-
UPC “saisie-contrefaçon” Part I: the texts
Random Articles:
-
Will the judgment of the CJEU in Seattle Genetics Inc allow you to recalculate the term of your SPC retrospectively?
-
Cross-Examination of French Judges (Interview Part I: National Introspection)
-
Spanish nullity actions against “unitary patent” Regulations: The CJEU, the procedures at the EPO and the impact on the Unified Patent Court Agreement
-
Even more on pemetrexed
-
The Italian Supreme Court on the limits of pharmacy exception
-
Clamps – An Open and Shut Case?
-
Dipeptidyl-Peptidase-Inhibitoren, Federal Court of Justice Germany, 11 September 2013
-
PDL Biopharma – humanized antibodies, European Patent Office (EPO Board of Appeal), 14 October 2009
-
Antibodies, Biologics, Case Law, Damages, Infringement, Injunction, Litigation, United Kingdom, Validity
How do you solve a problem like… valid and infringed patents?
-
New rules for post grant amendments in Italy